Pneumococcal Vaccine Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts

The Pneumococcal Vaccine Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Pneumococcal Vaccine Market Size During the Forecast Period?
Recent years have seen a significant increase in the size of the pneumococcal vaccine market. The market is projected to expand from $8.94 billion in 2024 to $9.49 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.2%. The historic period growth can be credited to factors such as the discovery of streptococcus pneumoniae, public health consciousness, preemptive vaccination drives, progress in healthcare, and revisions in vaccine policies.

The market size for pneumococcal vaccines is anticipated to witness robust expansion in the forthcoming years, reaching a value of $12.12 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%. This projected surge during the forecast period can be credited to the evolution of pneumococcal strains, ongoing R&D, prioritized immunizations, wider availability of vaccines, and an aging populace. Notable trends during this forecast period encompass the creation of multivalent vaccines, focusing on vaccination for high-risk groups, enhancing the efficiency of vaccines, emphasizing educational and awareness drives, and targeting vaccination for infants.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11950

What Are the High-Growth Segments in the Pneumococcal Vaccine Market?
The pneumococcal vaccine market covered in this report is segmented -

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products
2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous
3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels
4) By End User: Pediatrics, Adults

Subsegments:
1) By Prevnar 13: Pediatric Formulation, Adult Formulation
2) By Synflorix: Pediatric Formulation, Adult Formulation
3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes
4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Key Drivers Are Expected to Influence Future Pneumococcal Vaccine Market Growth?
The rise in instances of pneumococcal pollution is anticipated to bolster the expansion of the pneumococcal vaccine market. Pneumococcal pollution encompasses any infection instigated by Streptococcus pneumoniae or pneumococcus bacteria, such as pneumonia, infections in the bloodstream, ear infections, and sinus infections. The pneumococcal vaccine incites the body to manufacture antibodies that counter pneumococcal bacteria, diminishing or eradicating bacteria and toxins that cause disease and safeguarding children, the elderly, and those with compromised immune systems from various pneumococcal infections. For example, as reported by the US-based Center for Disease Control and Prevention in January 2022, it was estimated that Pneumococcal pneumonia led to approximately 150,000 hospitalizations annually in the United States, accounting for up to 30% of adult community-acquired pneumonia. Hence, the growing incidence of pneumococcal pollution is a significant factor propelling the expansion of the pneumococcal vaccine market.

Which Companies Hold the Largest Share Across Different Pneumococcal Vaccine Market Segments?
Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

What Trends Are Driving Growth in The Pneumococcal Vaccine Market?
Top-tier companies in the pneumococcal vaccine market are using product innovation to improve their market profit. For example, Merck & Co Inc., a pharmaceutical company from the US, introduced the V116 vaccine in July 2023. The vaccine V116 is designed to target the eight separate serotypes of Streptococcus pneumoniae that are predominantly behind adult pneumococcal diseases. V116 has demonstrated superior immunogenicity against numerous serotypes in adults compared to other pneumococcal vaccines and has also elicited positive immune reactions among individuals both new to and previously exposed to vaccination. The FDA in the U.S. has accorded V116 the status of a breakthrough therapy, and it's currently under Phase 3 development.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

What Are the Emerging Geographies for The Pneumococcal Vaccine Market Growth?
North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Pneumococcal Vaccine Market?
2. What is the CAGR expected in the Pneumococcal Vaccine Market?
3. What Are the Key Innovations Transforming the Pneumococcal Vaccine Industry?
4. Which Region Is Leading the Pneumococcal Vaccine Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.